60 Degrees Pharmaceuticals (SXTP) Current Leases (2022 - 2023)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Current Leases of $13650.0 for Q4 2023, up 5.0% year-over-year from $13000.0 in Q4 2022, and down 49.07% quarter-over-quarter from $26800.0 in Q3 2023.
60 Degrees Pharmaceuticals (SXTP) Current Leases (2022 - 2023) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Current Leases for 2 consecutive years, with $13650.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Current Leases rose 5.0% year-over-year to $13650.0; the TTM figure through Dec 2023 stood at $13650.0 (up 5.0% YoY), while the FY2023 annual figure was $13650.0, up 5.0% from the prior year.
- Current Leases retreated to $13650.0 in Q4 2023 per SXTP's latest filing, from $26800.0 in the prior quarter.
- Across five years, Current Leases topped out at $39470.0 in Q2 2023 and bottomed at $13000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13,650.00 |
| Sep 30, 2023 | 26,800.00 |
| Jun 30, 2023 | 39,470.00 |
| Dec 31, 2022 | 13,000.00 |